Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06842407

Acronym

Immuno-ab

Enrollment

600

Registered

2025-02-24

Start date

2023-04-01

Completion date

2026-06-30

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Donors

Brief summary

The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* blood donors * age of 18 years or more * able to sign informed consent

Exclusion criteria

* age below 18 years * Positive for HIV, HCV, HBV * not suitable for blood donation * not able to understand or sign informed consent

Design outcomes

Primary

Measure	Time frame
Validation of molecular targets for immunotherapy	04.2023-06.2026
Selection of therapeutic antibodies	04.2023-06.2026

Secondary

Measure	Time frame
Set up of immunological assays to adress monoclonal antibodies mechanism of action	04.2023-06.2026

Countries

Italy

Contacts

Primary ContactRenata M Grifantini, PhD

renata.grifantini@checkmab.eu0039 00660220

Outcome results